Suzhou Abogen Biosciences Co., Ltd. is advancing its lyophilized herpes zoster mRNA vaccine, ABO1108, targeting adults aged 40 years and older. The vaccine aims to address the significant market need for effective herpes zoster prevention, particularly in aging populations. The competitive landscape includes established vaccines like Shingrix, which may pose a challenge in terms of market penetration. The trial's focus on safety and immunogenicity will be critical for regulatory approval and subsequent market acceptance. Given the aging demographic and rising incidence of herpes zoster, successful outcomes could position ABO1108 favorably within the growing vaccine market, potentially leading to lucrative commercial opportunities.